🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

General Hospital of Shenyang Military Region clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with General Hospital of Shenyang Military Region as lead sponsor. Synced 26 Sep 2026
34Current trials
27Recruiting now
13Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

General Hospital of Shenyang Military Region is the lead sponsor of 34 current clinical trials in our China register. 27 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Pantoprazole, Tenecteplase and Atorvastatin Calcium. The most-studied condition is Ischemic Stroke.

ClinicalTrials.gov trials by status

  • Recruiting2779%
  • Not yet open412%
  • Active, closed26%
  • By invitation13%

Trials by phase

  • Not applicable2162%
  • Observational515%
  • Phase 2412%
  • Phase 439%
  • Phase 313%
01

Clinical trials sponsored by General Hospital of Shenyang Military Region

34 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Fingolimod for Type 2 Diabetes Mellitus
NCT05307731 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2
Phase 4 Recruiting 2022-03 China
The Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks
NCT07270887 · ClinicalTrials.gov ↗ · ASCVD
Observational Recruiting 2025-11 China
Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis
NCT07388420 · ClinicalTrials.gov ↗ · Hypertriglyceridemia Induced Acute Pancreatitis
Not applicable Recruiting 2026-01 China
Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK)
NCT07375953 · ClinicalTrials.gov ↗ · Ischemic Stroke
Phase 2 Recruiting 2026-03 China
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
NCT06483737 · ClinicalTrials.gov ↗ · Overt Hepatic Encephalopathy
Not applicable Recruiting 2025-06 China
The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients
NCT03571763 · ClinicalTrials.gov ↗ · Ischemic Stroke
Observational Recruiting 2018-08 China
High-resolution Magnetic Resonance Imaging of Intracranial Atherosclerotic Plaques in Ischemic Stroke
NCT05897645 · ClinicalTrials.gov ↗ · Stroke, Intracranial Atherosclerosis, High Resolution Magnetic Resonance Imaging
Observational Recruiting 2023-01 China
Transcranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS)
NCT07462546 · ClinicalTrials.gov ↗ · Artery Stenosis
Not applicable Recruiting 2026-03 China
The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques
NCT03753555 · ClinicalTrials.gov ↗ · Stroke, Ischemic, Atherosclerosis, Cerebral
Phase 4 Recruiting 2018-12 China
Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia
NCT06922669 · ClinicalTrials.gov ↗ · Drug Induced Liver Injury
Not applicable Recruiting 2025-06 China
Balloon Angioplasty for Minor Unstable Stroke With IntraCranial Atherosclerosis Stenosis (BAMUS-ICAS)
NCT06763458 · ClinicalTrials.gov ↗ · Ischemic Stroke
Not applicable Recruiting 2025-02 China
Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS)
NCT07283159 · ClinicalTrials.gov ↗ · Ischemic Stroke
Phase 2 Recruiting 2026-01 China
Head dOwn Position Before Endovascular Treatment for Large veSsel Occlusion (HOPES5)
NCT07172789 · ClinicalTrials.gov ↗ · Ischemic Stroke
Not applicable Recruiting 2025-09 China
Effects of Short-term Intensive Statin Therapy on Lipid Levels
NCT07344610 · ClinicalTrials.gov ↗ · Ischemic Stroke
Observational Recruiting 2026-01 China
Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2)
NCT07375966 · ClinicalTrials.gov ↗ · Ischemic Stroke
Phase 2 Recruiting 2026-03 China
Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion
NCT06383182 · ClinicalTrials.gov ↗ · Ischemic Stroke
Observational Recruiting 2024-07 China
Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Prourokinase
NCT07550296 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
Phase 2 Recruiting 2026-05 China
Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban
NCT07135089 · ClinicalTrials.gov ↗ · Stroke, Ischemic
Phase 3 Recruiting 2025-11 China
Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke
NCT06170944 · ClinicalTrials.gov ↗ · Stroke, Ischemic
Not applicable Recruiting 2024-06 China
Individualized Non-pharmacological Intervention for Bowel Preparation
NCT07684716 · ClinicalTrials.gov ↗ · Bowel Preparation for Colonoscopy
Not applicable Recruiting 2026-06 China
Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease
NCT07294885 · ClinicalTrials.gov ↗ · Alzheimer Disease
Not applicable Recruiting 2026-03 China
Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)
NCT06010628 · ClinicalTrials.gov ↗ · Stroke, Ischemic
Phase 4 Recruiting 2024-02 China
Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis
NCT07412249 · ClinicalTrials.gov ↗ · Carotid Stenosis
Not applicable Recruiting 2026-03 China
Trendelenburg Position for Acute Anterior Circulation Ischemic Stroke With Large Artery Atherosclerosis Etiology (HOPES 3)
NCT06010641 · ClinicalTrials.gov ↗ · Stroke, Acute Ischemic
Not applicable Recruiting 2024-01 China
Remote Ischemic Conditioning for Acute Moderate Posterior Ischemic Stroke
NCT06931535 · ClinicalTrials.gov ↗ · Ischemic Stroke
Not applicable Recruiting 2025-04 China
Efficacy and Safety of Local Glucocorticoids for the Treatment of Acute Radiation-Induced Intestinal Injury
NCT06410443 · ClinicalTrials.gov ↗ · Radiation-Induced Intestinal Injury
Not applicable Recruiting 2024-08 China
Direct Ischemic Conditioning for Endovascular Recanalization for Anterior Large Vessel Occlusion (DICER-aLVO)
NCT06940128 · ClinicalTrials.gov ↗ · Ischemic Stroke
Not applicable Recruiting 2025-03 China
Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9
NCT07652203 · Cirrhosis
Not applicable Not yet open 2026-09 China
Keverprazan vs Pantoprazole for the Treatment of ANVUGIB
NCT07776730 · ClinicalTrials.gov ↗ · Non-variceal Upper Gastrointestinal Bleeding
Not applicable Not yet open 2026-10 China
Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunction
NCT07252401 · ClinicalTrials.gov ↗ · Liver Cirrhosis
Not applicable Not yet open 2026-09 China
Dyclonine vs. Tetracaine for Local Anesthesia in Unsedated Gastroscopy
NCT07691346 · ClinicalTrials.gov ↗ · Gastrointestinal Symptoms
Not applicable Not yet open 2026-09 China
Pantoprazole After Prophylactic Endoscopic Variceal Treatment
NCT07248722 · ClinicalTrials.gov ↗ · Esophageal and Gastric Varices, Liver Cirrhosis
Not applicable By invitation 2026-03 China
Timing of Endoscopy in Cirrhotic Patients With Acute Variceal Bleeding
NCT06031402 · ClinicalTrials.gov ↗ · Acute Upper Gastrointestinal Bleeding, Acute Variceal Bleeding
Not applicable Active, closed 2024-09 China
Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD
NCT06984497 · ClinicalTrials.gov ↗ · End-Stage Liver Diseases
Not applicable Active, closed 2026-02 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in General Hospital of Shenyang Military Region trials

13 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in General Hospital of Shenyang Military Region trials

26 conditions
Ischemic Stroke10Stroke, Ischemic4Liver Cirrhosis2Cirrhosis1Diabetes Mellitus, Type 21ASCVD1Hypertriglyceridemia Induced Acute Pancreatitis1Overt Hepatic Encephalopathy1Stroke1Intracranial Atherosclerosis1High Resolution Magnetic Resonance Imaging1Artery Stenosis1Atherosclerosis, Cerebral1Drug Induced Liver Injury1Esophageal and Gastric Varices1Acute Upper Gastrointestinal Bleeding1Acute Variceal Bleeding1Non-variceal Upper Gastrointestinal Bleeding1Acute Ischemic Stroke1End-Stage Liver Diseases1Bowel Preparation for Colonoscopy1Alzheimer Disease1Carotid Stenosis1Stroke, Acute Ischemic1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China3427

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Ischemic Stroke

SponsorTrials
Beijing Tiantan Hospital10
Capital Medical University7
Affiliated Hospital of Nantong University3
Nanjing First Hospital, Nanjing Medical University3
Zhujiang Hospital3
Hui-Sheng Chen2
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine1
Shanghai IxCell Biotechnology1

Sponsors with the most current trials registered for this condition.

06

Questions about General Hospital of Shenyang Military Region trials

How many clinical trials does General Hospital of Shenyang Military Region sponsor?

General Hospital of Shenyang Military Region is the lead sponsor of 34 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are General Hospital of Shenyang Military Region trials recruiting?

Yes. 27 of its 34 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is General Hospital of Shenyang Military Region testing?

Its current trials name 13 drugs and biologicals as interventions. The most frequent are Pantoprazole (2), Tenecteplase (2), Atorvastatin Calcium (1), Branched-Chain Amino Acids (1) and Dexamethasone (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.